Certolizumab pegol
- 1 August 2008
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 7 (8) , 641-642
- https://doi.org/10.1038/nrd2654
Abstract
In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies.Keywords
This publication has 12 references indexed in Scilit:
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled TrialsClinical Gastroenterology and Hepatology, 2008
- Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agentsInflammatory Bowel Diseases, 2007
- Certolizumab Pegol for the Treatment of Crohn's DiseaseNew England Journal of Medicine, 2007
- Maintenance Therapy with Certolizumab Pegol for Crohn's DiseaseNew England Journal of Medicine, 2007
- Adalimumab Induction Therapy for Crohn Disease Previously Treated with InfliximabAnnals of Internal Medicine, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Drug Insight: antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel diseaseNature Clinical Practice Gastroenterology & Hepatology, 2006
- Evolving knowledge and therapy of inflammatory bowel diseaseNature Reviews Drug Discovery, 2006
- The immunological and genetic basis of inflammatory bowel diseaseNature Reviews Immunology, 2003
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997